Lestaurtinib information

Lestaurtinib
Clinical data
Routes of; administration	By mouth
ATC code	None;
Pharmacokinetic data
Protein binding	highly protein-bound, especially to α-1 acid glycoprotein
Metabolism	liver P450 (CYP34A) enzyme system
Identifiers
	IUPAC name (5S,6S,8R)-6-Hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one;
CAS Number	111358-88-4 ;
PubChem CID	126565;
IUPHAR/BPS	5672;
ChemSpider	112457 ;
UNII	DO989GC5D1;
KEGG	D04696 ;
ChEMBL	ChEMBL603469 ;
CompTox Dashboard (EPA)	DTXSID5046778 ;
Chemical and physical data
Formula	C26H21N3O4
Molar mass	439.471 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O;
	InChI InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1 ; Key:UIARLYUEJFELEN-LROUJFHJSA-N ;
	(what is this?) (verify)

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer.^[1] It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3),^[2] Janus kinase 2 (JAK2),^[3] tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.^[4]

^ ^a ^b ^c ^d Shabbir M, Stuart R (2010). "Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside". Expert Opinion on Investigational Drugs. 19 (3): 427–36. doi:10.1517/13543781003598862. PMID 20141349. S2CID 13558158.
^ Knapper S, Burnett AK, Littlewood T, et al. (November 2006). "A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy". Blood. 108 (10): 3262–70. doi:10.1182/blood-2006-04-015560. PMID 16857985.
^ Hexner EO, Serdikoff C, Jan M, et al. (June 2008). "Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders". Blood. 111 (12): 5663–71. doi:10.1182/blood-2007-04-083402. PMC 2424161. PMID 17984313.
^ Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). "Lestaurtinib". Drugs of the Future. 32 (3): 215. doi:10.1358/dof.2007.032.03.1084137.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[a-1] Shabbir M, Stuart R (2010). "Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside". Expert Opinion on Investigational Drugs. 19 (3): 427–36. doi:10.1517/13543781003598862. PMID 20141349. S2CID 13558158.

[pmid16857985-2] Knapper S, Burnett AK, Littlewood T, et al. (November 2006). "A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy". Blood. 108 (10): 3262–70. doi:10.1182/blood-2006-04-015560. PMID 16857985.

[pmid17984313-3] Hexner EO, Serdikoff C, Jan M, et al. (June 2008). "Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders". Blood. 111 (12): 5663–71. doi:10.1182/blood-2007-04-083402. PMC 2424161. PMID 17984313.

[4] Revill, P., Serradell, N., Bolos, J., Rosa, E. (2007). "Lestaurtinib". Drugs of the Future. 32 (3): 215. doi:10.1358/dof.2007.032.03.1084137.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Lestaurtinib information

and 28 Related for: Lestaurtinib information

Lestaurtinib

Janus kinase inhibitor

Erythropoietin

Dexamethasone

Interferon

Testosterone

Amitriptyline

Cytokine

Denosumab

Ritlecitinib

Fruquintinib

Nerve growth factor

Ectodysplasin A receptor

Interferon alfa

Ruxolitinib

Elranatamab

Osimertinib

Tofacitinib

Neurotrophic factors

Insulin

Bevacizumab

Growth factor

Nintedanib

Lymphokine

Wnt signaling pathway

Etanercept

HER2

Epidermal growth factor receptor

Clinical data


Routes of administration	By mouth^[1]
ATC code	None
Pharmacokinetic data
Protein binding	highly protein-bound, especially to α-1 acid glycoprotein^[1]
Metabolism	liver P450 (CYP34A) enzyme system^[1]
Identifiers
IUPAC name (5S,6S,8R)-6-Hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one
CAS Number	111358-88-4^N
PubChem CID	126565
IUPHAR/BPS	5672
ChemSpider	112457^N
UNII	DO989GC5D1
KEGG	D04696^Y
ChEMBL	ChEMBL603469^N
CompTox Dashboard (EPA)	DTXSID5046778
Chemical and physical data
Formula	C₂₆H₂₁N₃O₄
Molar mass	439.471 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O
InChI InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1^N Key:UIARLYUEJFELEN-LROUJFHJSA-N^N
^NY (what is this?) (verify)